Practical implication
PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.
The MHRA has updated its procedural guidance on the submission of briefing materials for scientific advice requests. This change mandates that organizations must provide complete briefing documents at the time of submission, significantly earlier in the process than previously required.
What changed: Starting in September 2026, it is mandatory for organizations to submit full briefing documents along with their scientific advice requests. This introduces an earlier checkpoint for preparing safety-related materials such as RMPs and PASS protocols.
Why it matters: This change necessitates that pharmacovigilance teams intensify their efforts to finalize safety documentation much earlier in the product development lifecycle, thereby increasing coordination between regulatory and pharmacovigilance teams.
Practical implication: PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.
View original source
Published from the Firecrawl policy change extraction pipeline.